文献速递MDS 与骨髓增殖性肿瘤白血病

阿扎胞苷在「真实世界」中的评估:加拿大安大略省1101例较高危骨髓增生异常综合征/低原始细胞计数急性髓系白血病患者

Azacitidine in the 'real-world': an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada.
PubMed 文献 · Br J Haematol · 2018-05-16

在加拿大安大略省评估1101例连续较高危MDS(IPSS中危-2/高危)及低原始细胞计数AML(原始细胞21-30%)患者接受阿扎胞苷的真实世界结局。中位生存期全队列为11.6个月,接受至少4周期者 landmark 分析为18.0个月;三种给药方案间总生存无差异(P=0.87)。

要点

  • 全队列中位生存期11.6个月(95%CI 10.7-12.4)。
  • 接受至少4周期者 landmark 分析中位生存期18.0个月(95%CI 16.6-19.1)。
  • 三种给药方案间总生存无差异(P=0.87)。

核心结论

  • 在较大危MDS/低原始细胞计数AML的真实世界评估中,观察到总生存低于预期;生存不因给药方案不同而异;接受至少4周期者的总生存更高,强化了持续给药直至实现治疗获益的必要性。

研究设计与样本

  • 在加拿大安大略省评估1101例连续较高危MDS(IPSS中危-2/高危)及低原始细胞计数AML(原始细胞21-30%)患者接受阿扎胞苷治疗的真实世界研究。

主要发现

  • 按给药方案,24.7%接受连续7天方案,12.4%接受连续6天方案,62.9%接受5-2-2方案。
  • 总体中位周期数为6(范围1-67);在692例(63%)接受至少4周期的患者中,中位周期数为8(范围6-14)。
  • 全队列 actuarial 中位生存期为11.6个月(95%CI 10.7-12.4)。
  • 接受至少4周期者的 landmark 分析中位生存期为18.0个月(95%CI 16.6-19.1)。
  • 三种给药方案间总生存无差异(P=0.87)。

局限性

  • 原文结论指出该真实世界评估中总生存低于预期。
  • 原文结论指出强化了持续给药直至实现治疗获益的必要性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The outcome of myelodysplastic syndrome (MDS) patients with uniformly higher-risk disease treated with azacitidine (AZA) in the 'real-world' remains largely unknown. We evaluated 1101 consecutive higher-risk MDS patients (International Prognostic Scoring System intermediate-2/high) and low-blast count acute myeloid leukaemia (AML; 21-30% blasts) patients treated in Ontario, Canada. By dosing schedule, 24·7% received AZA for seven consecutive days, 12·4% for six consecutive days and 62·9% by 5-2-2. Overall, median number of cycles was 6 (range 1-67) and 8 (range 6-14) when restricted to the 692 (63%) patients who received at least 4 cycles. The actuarial median survival was 11·6 months [95% confidence interval (CI) 10·7-12·4) for the entire cohort and 18·0 months (landmark analysis; 95% CI 16·6-19·1 months) for those receiving at least 4 cycles. There was no difference in overall survival (OS) between the 3 dosing schedules (P = 0·87). In our large 'real-world' evaluation of AZA in higher-risk MDS/low-blast count AML, we demonstrated a lower than expected OS. Reassuringly, survival did not differ by dosing schedules. The OS was higher in the 2/3 of patients who received at least 4 cycles of treatment, reinforcing the necessity of sustained administration until therapeutic benefits are realised. This represents the largest 'real-world' evaluation of AZA in higher-risk MDS/low-blast count AML.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Mozessohn L, Cheung MC, Fallahpour S, et al. Azacitidine in the 'real-world': an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada. Br J Haematol. 2018. PMID: 29767427. doi:10.1111/bjh.15273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。